Page last updated: 2024-10-17

bupropion and Depression

bupropion has been researched along with Depression in 152 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
" The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression"."9.41Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. ( Akbar, D; Cao, B; Ceban, F; Ho, R; Kwan, ATH; McIntyre, RS; Rhee, TG; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2023)
"A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue."9.34A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020)
"In treatment of depression with less than optimal response, augmentation with either aripiprazole or bupropion was cost-effective relative to switching to bupropion."9.27Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. ( Johnson, GR; Mohamed, S; Park, A; Scrymgeour, A; Yoon, J; Zisook, S, 2018)
"While the combination therapy of varenicline and sustained release bupropion (bupropion SR) for cigarette smoking cessation can increase smoking abstinence rates, it has also been associated with increases in self-reported depressive symptoms."9.20Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. ( Ebbert, JO; Elrashidi, MY; Hong, AS; Schroeder, DR, 2015)
"The efficacy, safety, and tolerability of combined bupropion versus placebo using duloxetine as active reference drug, in patients with a DSM-IV diagnosis of major depression with atypical features and a history of treatment resistance, were evaluated in this preliminary six-week study."9.19Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. ( De Berardis, D; De Pasquale, C; Fornaro, M; Fornaro, P; Iasevoli, F; Martino, M; Mattei, C; Mungo, S; Prestia, D; Vinciguerra, V, 2014)
"To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning."9.17Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013)
"Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers."9.16Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. ( Ahluwalia, JS; Benowitz, NL; Choi, WS; Cox, LS; Faseru, B; Mayo, MS; Nollen, NL; Okuyemi, KS; Tyndale, RF, 2012)
"Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial."9.15Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011)
"Bupropion and cognitive-behavioral treatment (CBT) for depression have been used as components of treatments designed to alleviate affective disturbance during smoking cessation."9.14Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. ( Abrantes, AM; Brown, RA; Kahler, CW; Leventhal, AM; Lloyd-Richardson, E; Niaura, R; Strong, DR, 2009)
"This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms."9.14A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."9.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
"This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers."9.12Bupropion and cognitive-behavioral treatment for depression in smoking cessation. ( Abrams, D; Abrantes, AM; Brown, RA; Kahler, CW; Lloyd-Richardson, EE; Miller, IW; Niaura, R; Strong, DR, 2007)
"Bupropion SR treatment is an efficacious aid to smoking cessation in patients with COPD."9.11Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. ( Huibers, MJ; Knipschild, PG; van Schayck, CP; Wagena, EJ; Wouters, EF, 2005)
"The influence of depressive symptoms on smoking cessation was examined among 600 African American smokers who participated in a randomized, placebo-controlled trial of sustained-release bupropion hydrochloride."9.11The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. ( Ahluwalia, JS; Catley, D; Harris, KJ; Mayo, MS; Okuyemi, KS; Pankey, E, 2005)
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet."9.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain."9.09Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. ( Davis, B; Semenchuk, MR, 2000)
"A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects."9.08A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997)
"The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy."8.82Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003)
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking."8.81Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002)
"Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019."8.12Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022)
"Taken together, these results in rats suggest that rapid hypoglycemia can induce an anhedonic state characterized by impaired consummatory responses to nutritional incentive stimuli and that can be alleviated by the antidepressant bupropion."8.02Evidence of hypoglycemic anhedonia and modulation by bupropion in rats. ( Ayoub, S; Horman, T; Leri, F, 2021)
"The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression."7.91The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019)
"Bupropion is used for treatment of depression during pregnancy."7.83Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016)
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders."7.79Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013)
"This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice."7.74Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008)
"A case of bupropion-induced constipation is reported."7.74Severe constipation associated with extended-release bupropion therapy. ( Green, CG; Lounsbery, JL; Medow, MA, 2008)
"To assess if certain personality factors (anxiety or depression) might predict the efficacy of bupropion for smoking cessation."7.71[Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy]. ( Carreras, JM; Coll, F; Lores, L; Quesada, M; Sampablo Lauro, I; Sánchez Agudo, L, 2002)
"To report a case of acute dystonia consisting of neck stiffness, trismus, and unilateral temporomandibular joint (TMJ) pain and subluxation secondary to an increase in sustained-release (SR) bupropion."7.71Bupropion-induced acute dystonia. ( Detweiler, MB; Harpold, GJ, 2002)
"Bupropion is a relatively new and popular medication with seizures as its major side effect."7.71Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. ( Avasarala, J; Pesola, GR, 2002)
"Bupropion was administered to a 45-year-old white man being treated for depression with psychosis."7.70Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999)
"To describe the first incidence of eosinophilia following administration of bupropion."7.69Eosinophilia associated with bupropion. ( Housel, GJ; Mahowald, JA; Malesker, MA; Malone, PM; Soori, GS, 1995)
"Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases."6.71Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005)
"Bupropion SR was associated with dose-related weight loss in all 3 studies."6.69Safety profile of sustained-release bupropion in depression: results of three clinical trials. ( Ascher, JA; Batey, SR; Johnston, JA; Settle, EC; Stahl, SM, 1999)
"Mean bupropion t1/2 was 34."6.68Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. ( Altieri, LP; DeVane, CL; Kirshner, M; Pollock, BG; Sweet, RA; Wright, B, 1995)
" Assessments of safety included vital signs, electrocardiogram, clinical laboratory tests, and adverse experiences."6.65Comparative efficacy and safety of bupropion and placebo in the treatment of depression. ( Brodie, HK; Fabre, L; Garver, D; McLendon, D; Zung, WW, 1983)
"Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required."6.50Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014)
"In older adults with treatment-resistant depression, augmentation of existing antidepressants with aripiprazole improved well-being significantly more over 10 weeks than a switch to bupropion and was associated with a numerically higher incidence of remission."5.69Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. ( Blumberger, DM; Brown, PJ; Cristancho, P; Flint, AJ; Gebara, MA; Gettinger, TR; Karp, JF; Lavretsky, H; Lenard, E; Lenze, EJ; Miller, JP; Mulsant, BH; Nicol, GE; Oughli, HA; Pham, VT; Reynolds, CF; Rollman, BL; Roose, SP; Yang, L, 2023)
"Bupropion was considered as a good candidate for such systems due to high water solubility that requires frequent dosing."5.56Formulation, Characterization and Comparative Pharmacokinetic Study of Bupropion Floating Raft System as a Promising Approach for Treating Depression. ( Abdel Hamid, MM; El-Nabarawi, MA; Jasti, BR; Shoman, NA; Teaima, MH; Yasser, M, 2020)
" BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase."5.51Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression. ( Ahmed, R; Bermudez, C; Boyd, BD; Christman, S; Elson, D; Kang, H; Landman, BA; Ryan, C; Szymkowicz, SM; Taylor, WD, 2022)
"Bupropion was found to reduce the negative biases in emotional processing early in treatment, including a significant decrease in the percentage misclassification of other face emotions as sad and the number of negative self-referent words falsely recalled between baseline and week 2."5.48Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression. ( Browning, M; Drevets, WC; Furey, M; Harmer, CJ; Walsh, AEL, 2018)
"Drug effects on formalin-induced mechanical allodynia were evaluated for comparison."5.43Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016)
" The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression"."5.41Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. ( Akbar, D; Cao, B; Ceban, F; Ho, R; Kwan, ATH; McIntyre, RS; Rhee, TG; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM, 2023)
"Aripiprazole and bupropion were comparable in significantly lowering patients' QIDS SR16 scores and helping over 50% of the patients achieve remission."5.40Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. ( Crayton, J; Nasr, S; Popli, A; Wendt, B, 2014)
"The response frequency to mechanical allodynia in mice was measured with von Frey hairs."5.36Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010)
"The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area."5.36Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010)
"A randomized, double-blind, placebo-controlled trial will examine the effects of bupropion on cancer-related fatigue."5.34A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures. ( Babilonia, MB; Bower, J; Cole, S; Culakova, E; Desta, Z; Han, HS; Heckler, C; Hoogland, AI; Janelsins, M; Jim, HSL; Morrow, G; Peppone, L; Williams, GC, 2020)
"Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity."5.31[Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000)
"This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine."5.30The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019)
"In treatment of depression with less than optimal response, augmentation with either aripiprazole or bupropion was cost-effective relative to switching to bupropion."5.27Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. ( Johnson, GR; Mohamed, S; Park, A; Scrymgeour, A; Yoon, J; Zisook, S, 2018)
"Platelet derived growth factor, basic fibroblast growth factor, and granulocyte colony stimulating factor were measured as part of Bioplex Pro human cytokine 27-plex kit in participants of the Combining Medications to Enhance Depression Outcomes trial who provided baseline plasma (n=166) and were treated with either bupropion-plus-escitalopram, escitalopram-plus-placebo, or venlafaxine-plus-mirtazapine."5.24Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. ( Gadad, BS; Jha, MK; Minhajuddin, A; Trivedi, MH, 2017)
"Participants were weight-concerned women (n = 349) ages 18-65 enrolled in a randomized, double-blind, placebo-controlled smoking cessation trial of bupropion and cognitive behavioral therapy."5.20A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms? ( Cheng, Y; Creswell, KG; Levine, MD, 2015)
"While the combination therapy of varenicline and sustained release bupropion (bupropion SR) for cigarette smoking cessation can increase smoking abstinence rates, it has also been associated with increases in self-reported depressive symptoms."5.20Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. ( Ebbert, JO; Elrashidi, MY; Hong, AS; Schroeder, DR, 2015)
"The efficacy, safety, and tolerability of combined bupropion versus placebo using duloxetine as active reference drug, in patients with a DSM-IV diagnosis of major depression with atypical features and a history of treatment resistance, were evaluated in this preliminary six-week study."5.19Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. ( De Berardis, D; De Pasquale, C; Fornaro, M; Fornaro, P; Iasevoli, F; Martino, M; Mattei, C; Mungo, S; Prestia, D; Vinciguerra, V, 2014)
"To assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning."5.17Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. ( Brown, VL; Cinciripini, PM; Engelmann, JM; Karam-Hage, M; Lam, C; Minnix, JA; Robinson, JD; Versace, F; Wetter, DW, 2013)
"Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study."5.17Increase in work productivity of depressed individuals with improvement in depressive symptom severity. ( Balasubramani, GK; Daly, E; Gaynes, BN; Kurian, BT; Lesser, I; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR, 2013)
"Previous research demonstrated the efficacy of sustained release bupropion (bupropion SR) for smoking cessation in whites as well as moderate to heavy (≥10 cigarettes per day [CPD]) African American smokers."5.16Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. ( Ahluwalia, JS; Benowitz, NL; Choi, WS; Cox, LS; Faseru, B; Mayo, MS; Nollen, NL; Okuyemi, KS; Tyndale, RF, 2012)
"Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial."5.15Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011)
"Bupropion and cognitive-behavioral treatment (CBT) for depression have been used as components of treatments designed to alleviate affective disturbance during smoking cessation."5.14Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. ( Abrantes, AM; Brown, RA; Kahler, CW; Leventhal, AM; Lloyd-Richardson, E; Niaura, R; Strong, DR, 2009)
"This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms."5.14A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010)
"This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life."5.12An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006)
"This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers."5.12Bupropion and cognitive-behavioral treatment for depression in smoking cessation. ( Abrams, D; Abrantes, AM; Brown, RA; Kahler, CW; Lloyd-Richardson, EE; Miller, IW; Niaura, R; Strong, DR, 2007)
"Bupropion SR treatment is an efficacious aid to smoking cessation in patients with COPD."5.11Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. ( Huibers, MJ; Knipschild, PG; van Schayck, CP; Wagena, EJ; Wouters, EF, 2005)
"The influence of depressive symptoms on smoking cessation was examined among 600 African American smokers who participated in a randomized, placebo-controlled trial of sustained-release bupropion hydrochloride."5.11The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. ( Ahluwalia, JS; Catley, D; Harris, KJ; Mayo, MS; Okuyemi, KS; Pankey, E, 2005)
"Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) received bupropion SR 300 mg/d or placebo for 26 weeks with a 500 kcal/d-deficit diet."5.10Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002)
"The purpose of this study was to assess the analgesic potential of sustained-release (SR) bupropion for neuropathic pain."5.09Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. ( Davis, B; Semenchuk, MR, 2000)
"A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects."5.08A comparison of sustained-release bupropion and placebo for smoking cessation. ( Croghan, IT; Dale, LC; Glover, ED; Glover, PN; Hurt, RD; Johnston, JA; Khayrallah, MA; Offord, KP; Sachs, DP; Schroeder, DR; Sullivan, CR; Sullivan, PM, 1997)
"We obtained access to IPD from seven placebo-controlled trials comparing bupropion, duloxetine, escitalopram, mirtazapine, paroxetine or venlafaxine with placebo in the acute phase treatment of major depression (total n = 2803)."5.01Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. ( Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S, 2019)
" This paper reviews the prevalence of sexual dysfunction, weight gain and emotional detachment during SSRI treatment, the profile of bupropion for each of these events and the ability of bupropion to reverse them."4.84Review: Bupropion and SSRI-induced side effects. ( Demyttenaere, K; Jaspers, L, 2008)
"The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the options available for smoking cessation pharmacotherapy."4.82Review of bupropion for smoking cessation. ( Richmond, R; Zwar, N, 2003)
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking."4.81Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002)
"Esketamine is a novel treatment for treatment resistant depression (TRD) and was approved by the FDA in early 2019."4.12Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. ( Cook, J; Halaris, A, 2022)
"Taken together, these results in rats suggest that rapid hypoglycemia can induce an anhedonic state characterized by impaired consummatory responses to nutritional incentive stimuli and that can be alleviated by the antidepressant bupropion."4.02Evidence of hypoglycemic anhedonia and modulation by bupropion in rats. ( Ayoub, S; Horman, T; Leri, F, 2021)
"The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression."3.91The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019)
"Bupropion is used for treatment of depression during pregnancy."3.83Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016)
"Varenicline does not seem to be associated with an increased risk of documented cardiovascular events, depression, or self-harm when compared with NRT."3.81Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. ( Kotz, D; Sheikh, A; Simpson, C; van Schayck, OC; Viechtbauer, W; West, R, 2015)
"The dopamine reuptake inhibitor bupropion and dopamine D2/3 receptor agonist pramipexole have been clinically proven to improve both depression and treatment-resistant depression."3.80Effects of bupropion and pramipexole on cell proliferation in the hippocampus of adrenocorticotropic hormone-treated rats. ( Asanuma, M; Kitamura, Y; Kuwatsuka, K; Miyazaki, I; Onoue, Y; Sendo, T, 2014)
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders."3.79Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013)
"To compare the risk of suicide, self harm, and depression in patients prescribed varenicline or bupropion with those prescribed nicotine replacement therapy."3.79Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. ( Davies, NM; Gunnell, D; Martin, RM; Metcalfe, C; Thomas, KH; Windmeijer, F, 2013)
"We assessed the effects of acute administration of bupropion (a dopamine-norepinephrine reuptake inhibitor) on spontaneous locomotor activity and depression-like behaviour (using the forced-swim test)."3.78Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction. ( Argyropoulos, A; Hannan, AJ; Renoir, T, 2012)
"Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement."3.77Suicidal behavior and depression in smoking cessation treatments. ( Furberg, CD; Glenmullen, J; Maltsberger, JT; Moore, TJ; Singh, S, 2011)
"The dopamine reuptake inhibitor bupropion has clinically been proven to improve depression and treatment-resistant depression."3.76Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. ( Asanuma, M; Gomita, Y; Kawasaki, H; Kitagawa, K; Kitamura, Y; Shinomiya, K; Yagi, T, 2010)
"This study assessed the effects of co-administration of bupropion with SSRIs: sertraline, paroxetine, citalopram, fluvoxamine, SNRIs: venlafaxine and milnacipran and NRI: desipramine, using an animal model of depression, the forced swimming test in mice."3.74Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? ( Bourin, M; Hascoet, M; Prica, C, 2008)
"A case of bupropion-induced constipation is reported."3.74Severe constipation associated with extended-release bupropion therapy. ( Green, CG; Lounsbery, JL; Medow, MA, 2008)
"Chronic nicotine infusion reduces the synthesis of 5HTT protein, which may consequently precipitate depression during nicotine withdrawal, but co-administration of bupropion may ameliorate withdrawal symptoms by counteracting nicotine's effect on 5HTT."3.74Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion. ( Semba, J; Wakuta, M, 2008)
" One month prior to her skin outbreak she was started on bupropion for mild depression."3.73Bupropion-induced subacute cutaneous lupus erythematosus. ( Callen, JP; Cassis, TB, 2005)
"To report a case of acute dystonia consisting of neck stiffness, trismus, and unilateral temporomandibular joint (TMJ) pain and subluxation secondary to an increase in sustained-release (SR) bupropion."3.71Bupropion-induced acute dystonia. ( Detweiler, MB; Harpold, GJ, 2002)
"Bupropion is a relatively new and popular medication with seizures as its major side effect."3.71Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. ( Avasarala, J; Pesola, GR, 2002)
"Bupropion was administered to a 45-year-old white man being treated for depression with psychosis."3.70Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999)
"To describe the first incidence of eosinophilia following administration of bupropion."3.69Eosinophilia associated with bupropion. ( Housel, GJ; Mahowald, JA; Malesker, MA; Malone, PM; Soori, GS, 1995)
"Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied."3.30Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. ( Ahn, YM; Arumugham, SS; Ashok, MV; Beaulieu, S; Bhandary, RP; Bond, DJ; Daigneault, A; Frey, BN; Ha, K; Kesavan, M; Kondapuram, N; Lam, RW; Milev, R; Murthy, NS; Ouyang, Y; Ramachandran, K; Ravindran, A; Ravindran, N; Reddy, MS; Reddy, YCJ; Saraf, G; Schaffer, A; Wong, H; Yatham, LN, 2023)
"Bupropion combinations were not superior to monotherapy (SMD = 0."2.82Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. ( Alexander, D; Baethge, C; Bschor, T; Henssler, J; Schwarzer, G, 2022)
"Bupropion pre-treatment had no statistically significant effect on the innate immune response to LPS or on LPS-induced behavioral changes, suggesting that 1-week pre-treatment with bupropion does not inhibit LPS-induced fatigue and anhedonia, contrary to what was found previously with citalopram."2.78Bupropion pre-treatment of endotoxin-induced depressive symptoms. ( DellaGioia, N; Devine, L; Hannestad, J; Pittman, B, 2013)
"Few studies have examined whether nicotine dependence self-report questionnaires can predict specific behaviors and symptoms at specific points in time."2.74Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures. ( Baker, TB; Bolt, DM; Japuntich, SJ; Piper, ME; Schlam, TR, 2009)
" Previous cost-effectiveness analyses have not fully accounted for adverse effects nor compared all cessation aids."2.72Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events. ( Caldwell, DM; Dalili, MN; Keeney, E; López-López, JA; Munafò, MR; Phillippo, DM; Stevenson, M; Thomas, KH; Welton, NJ, 2021)
"Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases."2.71Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. ( Audrain-McGovern, J; Brown, RA; Epstein, LH; Hawk, LW; Lerman, C; Niaura, R; Patterson, F; Wileyto, EP, 2005)
"When considering treating perinatal depression with a drug indicated for the treatment of depression, the major concerns are whether the drug increases the risks of teratogenicity, pregnancy complications, poor neonatal adaptation, or neurodevelopmental disorders."2.58Pharmacotherapy for Perinatal Depression. ( Albertini, ES; Ernst, C; Fersh, ME; Habib, S; Khan, SJ; Lusskin, SI, 2018)
"To assess the risk of headache associated with commonly prescribed antidepressant medications and to examine the impact of medication class, pharmacodynamics and dosage on risk of headache."2.58Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018)
"Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit."2.53Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. ( Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016)
"Bupropion may be an alternative treatment for depression that does not include the sexual side effects associated with most of the prescribed antidepressants available; however, additional research is required."2.50Bupropion in the depression-related sexual dysfunction: a systematic review. ( Arias-Carrión, O; Machado, S; Nardi, AE; Pereira, VM; Silva, AC, 2014)
"Preferred drugs for treating depression in epilepsy are serotonin reuptake inhibitors."2.49[Antidepressants in epilepsy]. ( Castaño-Monsalve, B, 2013)
"Psoriasis is a common condition, affecting 1."2.42Psychiatric morbidity in psoriasis: a review. ( Cooper, AJ; Ilchef, R; Russo, PA, 2004)
"Selegiline is a selective monoamine oxidase inhibitor used in the treatment of Parkinson's disease."2.40Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. ( Alexander, B; Ritter, JL, 1997)
" We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons."1.51Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice. ( Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019)
"Bupropion was found to reduce the negative biases in emotional processing early in treatment, including a significant decrease in the percentage misclassification of other face emotions as sad and the number of negative self-referent words falsely recalled between baseline and week 2."1.48Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression. ( Browning, M; Drevets, WC; Furey, M; Harmer, CJ; Walsh, AEL, 2018)
"Drug effects on formalin-induced mechanical allodynia were evaluated for comparison."1.43Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. ( Leitl, MD; Negus, SS, 2016)
"Aripiprazole and bupropion were comparable in significantly lowering patients' QIDS SR16 scores and helping over 50% of the patients achieve remission."1.40Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. ( Crayton, J; Nasr, S; Popli, A; Wendt, B, 2014)
"Depression is the leading psychiatric disorder with a high risk of morbidity and mortality."1.40Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. ( Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W, 2014)
"Fatigue is a common symptom in individuals with multiple sclerosis (MS)."1.39Reward responsiveness and fatigue in multiple sclerosis. ( Capello, E; Krueger, F; Mancardi, G; Pardini, M; Uccelli, A, 2013)
" When managing a patient with nonpsychotic depression and inadequate response to the maximum dose of a single antidepressant, the physician should first identify factors that may contribute to the poor response, such as suboptimal dosage resulting from nonadherence, inadequate duration of therapy, and comorbid medical and psychiatric conditions."1.36Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant? ( Lo, V; Maggio, L, 2010)
"The response frequency to mechanical allodynia in mice was measured with von Frey hairs."1.36Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. ( Jesse, CR; Nogueira, CW; Wilhelm, EA, 2010)
"The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area."1.36Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010)
"Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity."1.31[Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000)
"Bupropion is a novel antidepressant, distinct from tricyclic antidepressants both neurochemically and behaviorally."1.28Antidepressant profile of bupropion and three metabolites in mice. ( Colin, JN; Lacomblez, L; Martin, P; Massol, J; Puech, AJ, 1990)

Research

Studies (152)

TimeframeStudies, this research(%)All Research%
pre-19909 (5.92)18.7374
1990's11 (7.24)18.2507
2000's49 (32.24)29.6817
2010's58 (38.16)24.3611
2020's25 (16.45)2.80

Authors

AuthorsStudies
Yu, LF1
Zhang, HK1
Caldarone, BJ1
Eaton, JB1
Lukas, RJ1
Kozikowski, AP1
Ahmed, R3
Ryan, C1
Christman, S1
Elson, D3
Bermudez, C1
Landman, BA3
Szymkowicz, SM3
Boyd, BD3
Kang, H3
Taylor, WD3
Henssler, J1
Alexander, D1
Schwarzer, G1
Bschor, T1
Baethge, C1
Cinciripini, PM2
Kypriotakis, G1
Green, C1
Lawrence, D1
Anthenelli, RM1
Minnix, J1
Blalock, JA1
Beneventi, D1
Morris, C1
Karam-Hage, M2
Schwalsberger, K1
Reininghaus, B1
Reiter, A1
Dalkner, N1
Fleischmann, E1
Fellendorf, F1
Platzer, M1
Reininghaus, EZ1
Cook, J1
Halaris, A1
Peters, EM1
Balbuena, L1
Lodhi, RJ1
Chaki, S3
Watanabe, M3
Albert, K2
Begnoche, P2
Andrews, P2
Vega, J2
Zhang, H2
Gilbert, E2
Hussain, S2
Veldhuizen, S2
Le Foll, B2
Selby, P3
Zawertailo, L2
Lenze, EJ1
Mulsant, BH1
Roose, SP1
Lavretsky, H1
Reynolds, CF1
Blumberger, DM1
Brown, PJ1
Cristancho, P1
Flint, AJ1
Gebara, MA1
Gettinger, TR1
Lenard, E1
Miller, JP1
Nicol, GE1
Oughli, HA1
Pham, VT1
Rollman, BL1
Yang, L1
Karp, JF1
Yatham, LN1
Arumugham, SS1
Kesavan, M1
Ramachandran, K1
Murthy, NS1
Saraf, G1
Ouyang, Y1
Bond, DJ1
Schaffer, A1
Ravindran, A1
Ravindran, N1
Frey, BN1
Daigneault, A1
Beaulieu, S1
Lam, RW1
Kondapuram, N1
Reddy, MS1
Bhandary, RP1
Ashok, MV1
Ha, K1
Ahn, YM1
Milev, R1
Wong, H1
Reddy, YCJ1
Blaszczyk, AT1
Mathys, M1
Le, J1
Ebell, MH1
Akbar, D1
Rhee, TG1
Ceban, F1
Ho, R1
Teopiz, KM1
Cao, B1
Subramaniapillai, M1
Kwan, ATH1
Rosenblat, JD1
McIntyre, RS1
Kurogi, K1
Taniguchi, F1
Matsuo, R1
Shinozuka, M1
Suzaki, R1
Yasuo, S1
Jim, HSL1
Hoogland, AI1
Han, HS1
Culakova, E1
Heckler, C1
Janelsins, M1
Williams, GC1
Bower, J1
Cole, S1
Desta, Z1
Babilonia, MB1
Morrow, G1
Peppone, L1
de la Salle, S1
Jaworska, N2
Blier, P3
Smith, D1
Knott, V2
Puri, S1
Coplan, BM1
McGuire, PR1
Teaima, MH1
Abdel Hamid, MM1
Shoman, NA1
Jasti, BR1
El-Nabarawi, MA1
Yasser, M1
de Almeida, GRL1
Szczepanik, JC1
Selhorst, I1
Schmitz, AE1
Dos Santos, B1
Cunha, MP1
Heinrich, IA1
de Paula, GC1
De Bem, AF1
Leal, RB1
Dafre, AL1
Cândido, RCF1
Menezes de Padua, CA1
Golder, S1
Junqueira, DR1
Horman, T1
Ayoub, S1
Leri, F1
Keeney, E1
Welton, NJ1
Stevenson, M1
Dalili, MN1
López-López, JA1
Caldwell, DM1
Phillippo, DM1
Munafò, MR1
Thomas, KH3
Sathe, AR1
Thiemann, A1
Toulouie, S1
Durant, E1
Jha, MK2
Minhajuddin, A2
Gadad, BS1
Trivedi, MH5
Secades-Villa, R1
González-Roz, A1
García-Pérez, Á1
Becoña, E1
Walsh, AEL1
Browning, M1
Drevets, WC1
Furey, M1
Harmer, CJ1
Wakhlu, S1
Dronamraju, N1
Greer, TL1
Lusskin, SI1
Khan, SJ1
Ernst, C1
Habib, S1
Fersh, ME1
Albertini, ES1
Telang, S1
Walton, C1
Olten, B1
Bloch, MH1
Kim, EJ1
Felsovalyi, K1
Young, LM1
Shmelkov, SV1
Grunebaum, MF1
Cardozo, T1
De La Garza, N1
Rush, AJ3
Killian, MO1
Grannemann, BD1
Carmody, TJ1
Frizzell, W1
Howard, L1
Norris, HC1
Chien, J1
Yoon, J1
Zisook, S1
Park, A1
Johnson, GR1
Scrymgeour, A1
Mohamed, S1
Noma, H1
Furukawa, TA1
Maruo, K1
Imai, H1
Shinohara, K1
Tanaka, S1
Ikeda, K1
Yamawaki, S1
Cipriani, A1
Kawai, H1
Iwadate, R1
Ishibashi, T1
Kudo, N1
Kawashima, Y1
Mitsumoto, A1
Bendale, M1
DSouza, SR1
Addepalli, V1
Kale, PP1
Robinson, JD1
Minnix, JA1
Lam, C1
Versace, F1
Brown, VL1
Engelmann, JM1
Wetter, DW1
Morris, DW2
Wisniewski, SR2
Lesser, I1
Nierenberg, AA2
Daly, E1
Kurian, BT2
Gaynes, BN1
Balasubramani, GK1
Castaño-Monsalve, B1
Hays, JT1
Gibbons, RD1
Mann, JJ1
Barsevick, AM1
Irwin, MR1
Hinds, P1
Miller, A1
Berger, A1
Jacobsen, P1
Ancoli-Israel, S1
Reeve, BB1
Mustian, K1
O'Mara, A1
Lai, JS1
Fisch, M1
Cella, D1
Maciel, IS1
Silva, RB1
Morrone, FB1
Calixto, JB1
Campos, MM1
Martin, RM2
Davies, NM2
Metcalfe, C2
Windmeijer, F2
Gunnell, D2
Davies, SP1
Nunes, EJ2
Randall, PA2
Hart, EE1
Freeland, C1
Yohn, SE2
Baqi, Y2
Müller, CE2
López-Cruz, L1
Correa, M2
Salamone, JD2
Onoue, Y1
Kuwatsuka, K1
Miyazaki, I1
Asanuma, M2
Kitamura, Y2
Sendo, T1
Blondeau, C1
Tessier, P1
Norris, S1
Fusee, W1
Nasr, S1
Wendt, B1
Popli, A1
Crayton, J1
Fornaro, M1
Martino, M1
Mattei, C1
Prestia, D1
Vinciguerra, V1
De Berardis, D1
De Pasquale, C1
Iasevoli, F1
Mungo, S1
Fornaro, P1
Pereira, VM1
Arias-Carrión, O1
Machado, S1
Nardi, AE1
Silva, AC1
Lee, CA1
Nowak, V1
Khan, B1
Shah, P1
Pandit, S1
Vemuri, VK1
Makriyannis, A1
Renoir, T1
Argyropoulos, A1
Hannan, AJ1
Creswell, KG1
Cheng, Y1
Levine, MD1
Mlyniec, K1
Ostachowicz, B1
Krakowska, A1
Reczynski, W1
Opoka, W1
Nowak, G1
Hong, AS1
Elrashidi, MY1
Schroeder, DR2
Ebbert, JO1
Weissman, MM1
Wickramaratne, P1
Pilowsky, DJ1
Poh, E1
Batten, LA1
Hernandez, M1
Flament, MF1
Stewart, JA1
McGrath, P1
Stewart, JW2
Coiro, MJ1
Kotz, D1
Viechtbauer, W1
Simpson, C1
van Schayck, OC1
West, R1
Sheikh, A1
Roni, MA1
Rahman, S1
Leitl, MD1
Negus, SS1
Thorkelson, G1
Bielefeldt, K1
Szigethy, E1
Fokina, VM1
West, H1
Oncken, C1
Clark, SM1
Ahmed, MS1
Hankins, GD1
Nanovskaya, TN1
Jiménez Ruiz, CA1
Riesco Miranda, JA1
Roopan, S1
Larsen, ER1
Prica, C1
Hascoet, M2
Bourin, M2
Lounsbery, JL1
Medow, MA1
Green, CG1
Semba, J1
Wakuta, M1
Iñiguez, SD1
Warren, BL1
Parise, EM1
Alcantara, LF1
Schuh, B1
Maffeo, ML1
Manojlovic, Z1
Bolaños-Guzmán, CA1
Arias, HR1
Strong, DR2
Kahler, CW2
Leventhal, AM1
Abrantes, AM2
Lloyd-Richardson, E1
Niaura, R3
Brown, RA3
Lebovits, A1
Hainline, B1
Stone, LS1
Seminowicz, DA1
Brunz, JT1
Rosenquist, RW1
Cowan, P1
Japuntich, SJ1
Piper, ME1
Schlam, TR1
Bolt, DM1
Baker, TB2
Schnoll, RA1
Martinez, E1
Tatum, KL1
Weber, DM1
Kuzla, N1
Glass, M1
Ridge, JA1
Langer, C1
Miyamoto, C1
Wileyto, EP2
Leone, F1
Englisch, S1
Esser, A1
Zink, M1
Lo, V1
Maggio, L1
Bares, M1
Brunovsky, M1
Novak, T1
Kopecek, M1
Stopkova, P1
Sos, P1
Krajca, V1
Höschl, C1
Yagi, T1
Kitagawa, K1
Shinomiya, K1
Kawasaki, H2
Gomita, Y1
Jesse, CR1
Wilhelm, EA1
Nogueira, CW1
Raskin, S1
Durst, R1
Bobo, WV1
Chen, H1
Fava, M1
Warden, D1
Luther, JF1
Husain, MM1
Cook, IA1
Lesser, IM1
Kornstein, SG1
Shelton, RC2
Takechi, K1
Suemaru, K1
Araki, H1
Moore, TJ1
Furberg, CD1
Glenmullen, J1
Maltsberger, JT1
Singh, S1
Cox, LS1
Nollen, NL1
Mayo, MS2
Choi, WS1
Faseru, B1
Benowitz, NL1
Tyndale, RF1
Okuyemi, KS2
Ahluwalia, JS2
Lung, D1
Yeh, K1
Kiang, C1
Pardini, M1
Capello, E1
Krueger, F1
Mancardi, G1
Uccelli, A1
DellaGioia, N1
Devine, L1
Pittman, B1
Hannestad, J1
Tonstad, S1
Sampablo Lauro, I1
Carreras, JM1
Lores, L1
Quesada, M1
Coll, F1
Sánchez Agudo, L1
Jain, AK1
Kaplan, RA1
Gadde, KM1
Wadden, TA1
Allison, DB1
Brewer, ER1
Leadbetter, RA1
Richard, N1
Haight, B1
Jamerson, BD1
Buaron, KS1
Metz, A1
Smith, SS1
Jorenby, DE1
Leischow, SJ1
Nides, MA1
Rennard, SI1
Johnston, JA3
Jamerson, B1
Fiore, MC1
Richmond, R1
Zwar, N1
Ripoll, N1
David, DJ1
Dailly, E1
Tomarken, AJ1
Dichter, GS1
Freid, C1
Addington, S1
Fakhfakh, R1
Hsairi, M1
Gharbi, L1
Aouina, H1
Bouacha, H1
Achour, N1
Wax, CM1
Russo, PA1
Ilchef, R1
Cooper, AJ1
Prochaska, JJ2
Rossi, JS2
Redding, CA2
Rosen, AB2
Tsoh, JY2
Humfleet, GL1
Eisendrath, SJ1
Meisner, MR1
Hall, SM2
Yamada, J1
Sugimoto, Y1
Yamada, S1
Haug, NA1
Humfleet, G1
Delucchi, K1
Eisendrath, S1
Patterson, F1
Epstein, LH1
Audrain-McGovern, J1
Hawk, LW1
Lerman, C1
Moss, EL1
Simpson, JS1
Pelletier, G1
Forsyth, P1
Cassis, TB1
Callen, JP1
Wagena, EJ1
Knipschild, PG1
Huibers, MJ1
Wouters, EF1
van Schayck, CP1
Catley, D1
Harris, KJ1
Pankey, E1
Dobkin, RD1
Menza, M1
Marin, H1
Allen, LA1
Rousso, R1
Leiblum, SR1
Basson, R1
Brotto, LA1
Laan, E1
Redmond, G1
Utian, WH1
McCreadie, R1
Chan, CH1
Liu, HC1
Huang, MC1
Padala, PR1
Madaan, V1
Sattar, SP1
Dhir, A1
Kulkarni, SK1
Grandas, F1
López-Manzanares, L1
Lloyd-Richardson, EE1
Abrams, D1
Miller, IW1
Moura, MA1
Dattilo, PB1
Nordin, C1
Aylwin, S1
Al-Zaman, Y1
Demyttenaere, K1
Jaspers, L1
Zung, WW1
Brodie, HK1
Fabre, L1
McLendon, D1
Garver, D1
Ajac, IK1
Giroux, LJ1
Hill, JA1
Cooper, TB1
Suckow, RF1
Glassman, A1
Hughes, S1
Barnett, S1
Sosnouski, P1
Kirksey, DF1
Fogel, P1
Mamer, OA1
Chouinard, G2
Farrell, PG1
Stern, WC1
Harto-Truax, N1
Annable, L1
Langlois, R1
Briggs, GG1
Samson, JH1
Ambrose, PJ1
Schroeder, DH1
Malesker, MA1
Soori, GS1
Malone, PM1
Mahowald, JA1
Housel, GJ1
Sweet, RA1
Pollock, BG1
Kirshner, M1
Wright, B1
Altieri, LP1
DeVane, CL1
Ritter, JL1
Alexander, B1
Hurt, RD1
Sachs, DP1
Glover, ED1
Offord, KP1
Dale, LC1
Khayrallah, MA1
Glover, PN1
Sullivan, CR1
Croghan, IT1
Sullivan, PM1
Settle, EC1
Stahl, SM1
Batey, SR1
Ascher, JA1
Yolles, JC1
Armenta, WA1
Alao, AO1
Semenchuk, MR1
Davis, B1
Weintraub, D1
Linder, MW1
Leentjens, AF1
Verhey, FR1
Vreeling, FW1
Detweiler, MB1
Harpold, GJ1
Pesola, GR1
Avasarala, J1
Sullivan, MA1
Covey, LS1
Cohen, LJ1
Grothe, DR1
Harsch, HH1
Feinberg, M1
Martin, P1
Massol, J1
Colin, JN1
Lacomblez, L1
Puech, AJ1

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With[NCT01456936]Phase 48,144 participants (Actual)Interventional2011-11-30Completed
Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood[NCT00550667]1,120 participants (Actual)Observational2007-10-01Completed
Smoking Cessation Treatment for Substance Use Dependents[NCT03551704]120 participants (Anticipated)Interventional2018-01-15Recruiting
A Randomised Controlled Trial Evaluating the Efficacy and Mechanisms of a Ketogenic Diet as an Adjunctive Treatment for People With Treatment-resistant Depression[NCT06091163]100 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Combining Medications to Enhance Depression Outcomes[NCT00590863]Phase 4665 participants (Actual)Interventional2008-03-31Completed
CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)[NCT01421342]Phase 31,522 participants (Actual)Interventional2012-12-31Completed
Pharmacogenetics, Emotional Reactivity and Smoking[NCT00507728]Phase 2/Phase 3646 participants (Actual)Interventional2005-12-08Completed
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306]60 participants (Anticipated)Interventional2023-05-17Recruiting
Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329]80 participants (Anticipated)Interventional2018-05-13Recruiting
[NCT02681848]180,000 participants (Anticipated)Observational2006-09-01Active, not recruiting
Combining Antidepressants to Hasten Remission From Depression[NCT00519428]Phase 4245 participants (Actual)Interventional2007-08-31Completed
Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.[NCT01930422]34 participants (Actual)Interventional2013-07-31Completed
Tobacco Treatment for Employable Californians (TTEC), Improving Employability Partnership: Alliance to Curb Tobacco (Total IMPACT)[NCT02478697]360 participants (Actual)Interventional2015-10-31Completed
Bio-behavioral Lung Cancer Prevention Program[NCT00322205]Phase 4555 participants Interventional1999-06-30Completed
Telemedicine for Smoking Cessation in Rural Primary Care[NCT00843505]Phase 3566 participants (Actual)Interventional2009-06-30Completed
High Dose Bupropion Treatment for Smoking Cessation - Pilot Study[NCT03326128]Phase 212 participants (Actual)Interventional2021-09-01Terminated (stopped due to Due to the COVID-19 pandemic, it was difficult to recruit eligible participants.)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation[NCT00633321]Phase 2522 participants (Anticipated)Interventional2007-05-31Completed
The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population[NCT01015170]Phase 4454 participants (Actual)Interventional2009-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID33.5
Bupropion 150 mg BID22.6
NRT Patch23.4
Placebo12.5

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID38.0
Bupropion 150 mg BID26.1
NRT Patch26.4
Placebo13.7

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID29.2
Bupropion 150 mg BID19.3
NRT Patch20.4
Placebo11.4

CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID21.8
Bupropion 150 mg BID16.2
NRT Patch15.7
Placebo9.4

CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID25.5
Bupropion 150 mg BID18.8
NRT Patch18.5
Placebo10.5

CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID18.3
Bupropion 150 mg BID13.7
NRT Patch13.0
Placebo8.3

"Clinical Global Impression of Improvement (CGI-I), No Change Rating by Visit"

"The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as normal, not at all ill on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as no change on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs." (NCT01456936)
Timeframe: Baseline to Week 24

,,,
Interventionpercentage of participants (Number)
Week 1 (N= 1986, 1974, 1986, 1982)Week 2 (N= 1934, 1936, 1927, 1926)Week 3 (N= 1880, 1892, 1880, 1863)Week 4 (N= 1860, 1856, 1858, 1834)Week 5 (N= 1828, 1816, 1822, 1802)Week 6 (N= 1816, 1808, 1820, 1773)Week 8 (N= 1758, 1756, 1755, 1738)Week 10 (N= 1717, 1707, 1715, 1675)Week 12 (N= 1558, 1572, 1540, 1492)Week 13 (N= 1612, 16081602, 1575)Week 16 (N= 1586, 1606, 1568, 1541)Week 20 (N= 1563, 1573, 1523, 1510)Week 24 (N= 1533, 1515, 1499, 1497)
Bupropion 150 mg BID93.290.889.888.086.586.583.681.775.176.776.775.072.3
NRT Patch94.690.588.787.185.585.182.880.472.275.273.972.271.1
Placebo95.191.287.986.385.484.181.979.271.374.973.471.771.1
Varenicline 1.0 mg BID94.290.888.386.685.785.282.480.672.975.974.273.471.8

7-Day Point Prevalence of Abstinence (Overall)

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.117.922.324.425.726.930.226.530.427.630.727.126.529.229.225.127.927.827.923.926.726.427.023.2
NRT Patch0.914.220.023.525.126.831.328.032.128.032.127.626.929.429.224.928.128.228.123.726.526.325.323.6
Placebo1.010.312.113.113.614.617.915.918.115.518.816.016.019.119.816.118.819.519.216.318.818.418.315.7
Varenicline 1.0 mg BID1.318.826.330.433.435.839.537.441.638.742.539.636.839.538.533.136.436.235.730.833.933.833.029.8

7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.021.326.627.729.831.435.231.034.931.034.130.530.733.533.228.531.931.331.227.530.329.930.626.0
NRT Patch1.215.522.125.927.830.435.131.434.831.134.930.429.932.032.428.131.431.731.226.329.329.028.327.0
Placebo1.511.413.614.514.915.919.216.719.016.920.817.817.220.421.318.220.120.820.818.220.120.320.317.4
Varenicline 1.0 mg BID1.720.930.034.338.441.044.442.347.142.446.644.441.144.543.837.240.740.939.935.138.138.737.633.6

7-Day Point Prevalence of Abstinence, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.214.618.121.321.822.725.422.126.024.327.423.922.625.025.321.924.024.524.720.423.222.923.520.4
NRT Patch0.713.017.921.122.423.327.524.629.425.029.424.924.026.826.021.824.824.725.125.123.723.622.220.1
Placebo0.59.210.711.812.413.416.615.017.214.017.214.214.817.818.313.917.418.217.617.617.516.516.414.0
Varenicline 1.0 mg BID1.016.822.726.628.530.834.832.736.235.138.635.032.734.733.429.132.331.731.626.629.729.128.526.1

Estimated NPS AE Rate (%), by Cohort

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Least Squares Mean)
Non-psychiatric cohort (N=3984)Psychiatric cohort (N= 4074)
Bupropion 150 mg BID2.446.62
NRT Patch2.315.20
Placebo2.524.83
Varenicline 1.0 mg BID1.256.42

HADS Total Score (Overall)

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 1989, 1976, 1985, 1987)Week 2 (N= 1938, 1937, 1931, 1929)Week 3 (N= 1882, 1891, 1881, 1867)Week 4 (N= 1858, 1854, 1863, 1831)Week 5 (N= 1829, 1815, 1820, 1797)Week 6 (N= 1816, 1807, 1821, 1771)Week 8 (N= 1755, 1754, 1755, 1736)Week 10 (N= 1717, 1709, 1716, 1669)Week 12 (N= 1562, 1571, 1548, 1491)Week 13 (N= 1610, 1608, 1603, 1570)Week 16 (N= 1579, 1602, 1566, 1537)Week 20 (N= 1555, 1569, 1525, 1509)Week 24 (N= 1528, 1512, 1495, 1487)
Bupropion 150 mg BID5.615.064.604.394.164.054.103.863.793.663.773.733.80
NRT Patch4.954.744.484.314.084.013.964.003.783.713.783.723.82
Placebo5.054.804.384.394.144.094.124.043.953.703.823.753.62
Varenicline 1.0 mg BID5.034.684.314.153.943.823.823.853.643.603.673.653.62

HADS Total Score, Psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 1026, 1017, 1015, 1015)Week 2 (N= 1005, 1004, 996, 995)Week 3 (N= 947, 961, 945, 926)Week 4 (N= 935, 938, 929, 908)Week 5 (N= 918, 918, 914, 895)Week 6 (N= 917, 914, 912, 874)Week 8 (N= 887, 893, 878, 859)Week 10 (N= 864, 865, 864, 823)Week 12 (N= 790, 803, 798, 749)Week 13 (N= 813, 812, 814, 763)Week 16 (N= 795, 805, 791, 748)Week 20 (N= 784, 784, 763, 737)Week 24 (N= 770, 764, 758, 729)
Bupropion 150 mg BID7.586.996.516.366.035.875.965.725.665.445.625.545.69
NRT Patch6.826.646.306.165.825.625.635.645.445.365.445.465.57
Placebo6.706.426.026.045.805.755.635.555.425.095.375.265.04
Varenicline 1.0 mg BID6.766.425.995.875.585.395.435.385.175.065.265.175.21

Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 984, 972, 989, 992)Week 2 (N= 961, 954, 963, 970)Week 3 (N= 935, 930, 936, 941)Week 4 (N= 923, 916, 934, 923)Week 5 (N= 911, 897, 906, 902)Week 6 (N= 899, 893, 909, 897)Week 8 (N= 868, 861, 877, 877)Week 10 (N= 853, 844, 852, 846)Week 12 (N= 772, 768, 750, 742)Week 13 (N= 797, 796, 789, 807)Week 16 (N= 784, 797, 775, 789)Week 20 (N= 771, 785, 762, 772)Week 24 (N= 758, 748, 737, 758)
Bupropion 150 mg BID3.583.072.642.362.242.182.161.961.831.851.901.931.87
NRT Patch3.062.842.632.462.322.402.282.332.012.012.091.972.01
Placebo3.383.202.772.772.482.482.642.572.462.382.342.312.25
Varenicline 1.0 mg BID3.262.912.612.402.292.232.172.292.072.112.052.102.01

Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Number)
Non-psychiatric cohort (N= 990, 989, 1006, 999)Psychiatric cohort (N= 1026, 1017, 1016, 1015)Overall (N= 2016, 2006, 2022, 2014)
Bupropion 150 mg BID2.26.74.5
NRT Patch2.55.23.9
Placebo2.44.93.7
Varenicline 1.0 mg BID1.36.54.0

Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Number)
Non-psychiatric cohort (N= 990, 989, 1006, 999)Psychiatric cohort (N= 1026, 1017, 1016, 1015)Overall (N= 2016, 2006, 2022, 2014)
Bupropion 150 mg BID0.41.40.9
NRT Patch0.31.40.8
Placebo0.51.30.9
Varenicline 1.0 mg BID0.11.40.7

Occurrence of the Components of NPS AE Primary Endpoint (Overall)

The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below. (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling AbnormalHostilityAgitationAggressionDelusionsHallucinationManiaPanic DisorderParanoiaPsychosisHomicidal IdeationSuicidal BehaviorSuicidal IdeationSuicide
Bupropion 150 mg BID54114012141020120230
NRT Patch670140922514041150
Placebo5600331102810210151
Varenicline 1.0 mg BID570035171677140150

Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)

"The NPS AE endpoint was the occurrence of at least 1 treatment-emergent severe AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent severe AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling AbnormalHostilityAgitationAggressionDelusionsHallucinationManiaPanic DisorderParanoiaPsychosisSuicidal BehaviorSuicidal IdeationSuicideHomicidal Ideation
Bupropion 150 mg BID5411120112122000
NRT Patch6701600001040101
Placebo5600210002211010
Varenicline 1.0 mg BID5700120020141100

Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
Anxiety (severe)Depression (severe)Feeling abnormal (severe only)Hostility (severe)Agitation (moderate and severe)Aggression (moderate and severe)Delusions (moderate and severe)Hallucinations (moderate and severe)Mania (moderate and severe)Panic (moderate and severe)Paranoia (moderate and severe)Psychosis (moderate and severe)Homicidal ideation (moderate and severe)Suicidal behavior (moderate and severe)Suicidal ideation (moderate and severe)Suicide (moderate and severe)
Bupropion 150 mg BID10011130014100110
NRT Patch00011921021011120
Placebo30001130023000031
Varenicline 1.0 mg BID01001030100000000

Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
Anxiety (severe)Depression (severe)Feeling abnormal (severe only)Hostility (severe)Agitation (moderate and severe)Aggression (moderate and severe)Delusions (moderate and severe)Hallucinations (moderate and severe)Mania (moderate and severe)Panic (moderate and severe)Paranoia (moderate and severe)Psychosis (moderate and severe)Homicidal ideation (moderate and severe)Suicidal behavior (moderate and severe)Suicidal ideation (moderate and severe)Suicide (moderate and severe)
Bupropion 150 mg BID441029914916020120
NRT Patch670021712313030030
Placebo26002280267210120
Varenicline 1.0 mg BID560025141577140150

Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling abnormalHostilityAgitationAggressionDelusionsHallucinationsManiaPanicParanoiaPsychosisHomicidal ideationSuicidal behaviorSuicidal ideationSuicide
Bupropion 150 mg BID1001010001000100
NRT Patch0001200001000000
Placebo3000000001000011
Varenicline 1.0 mg BID0100010000000000

Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling abnormalHostilityAgitationAggressionDelusionsHallucinationsManiaPanicParanoiaPsychosisHomicidal ideationSuicidal behaviorSuicidal ideationSuicide
Bupropion 150 mg BID4410110111010100
NRT Patch6700400000010010
Placebo2600210001000100
Varenicline 1.0 mg BID5600110020000110

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID9430104
NRT Patch7500013
Placebo6490116
Varenicline 1.0 mg BID6480007

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID15240006119
NRT Patch11838302123
Placebo12939814331
Varenicline 1.0 mg BID14338606034

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID14335705115
NRT Patch11133302020
Placebo12334913225
Varenicline 1.0 mg BID13733806027

Quality of Life Inventory

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Interventionunits on a scale (Mean)
Escitalopram + Bupropion SR0.6
Venlafaxine XR + Mirtazapine0.4
Escitalopram + Placebo0.4

Quick Inventory of Depressive Symptoms

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Interventionpercentage of participants (Number)
Escitalopram + Bupropion SR46.6
Venlafaxine XR + Mirtazapine41.8
Escitalopram + Placebo46.0

Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase

Relapse in symptoms of major depression defined as a QIDS-C16 => 11 among those achieving remission in the acute phase. (NCT01421342)
Timeframe: Within 36 weeks after randomization (initiation of treatment)

InterventionParticipants (Count of Participants)
Switching: Bupropion-SR26
Augmenting: Antidepressant + Bupropion-SR35
Augmenting: Antidepressant + Aripiprazole37

Rate of Protocol Remission of Symptoms of Major Depressive Disorder

Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of <= 5 for two consecutive visits. (NCT01421342)
Timeframe: During acute phase (12 weeks)

InterventionParticipants (Count of Participants)
Switching: Bupropion-SR114
Augmenting: Antidepressant + Bupropion-SR136
Augmenting: Antidepressant + Aripiprazole146

Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)

Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)

InterventionParticipants (Count of Participants)
Switching: Bupropion-SR319
Augmenting: Antidepressant + Bupropion-SR332
Augmenting: Antidepressant + Aripiprazole375

Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale

Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved). (NCT01421342)
Timeframe: During acute phase (up to 12 weeks)

InterventionParticipants (Count of Participants)
Switching: Bupropion-SR356
Augmenting: Antidepressant + Bupropion-SR376
Augmenting: Antidepressant + Aripiprazole400

Symptoms of Depression Using the Center for Epidemiologic Studies Depression Scale (CES-D)

Symptoms of nicotine withdrawal measured using Center for Epidemiologic Studies Depression Scale (CES-D). Center of Epidemiologic Studies Depression Scale (CESD) a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

Interventionscore on a scale (Least Squares Mean)
Varenicline w/o DRD2 A1 Allele8.084
Varenicline With DRD2 A1 Allele6.847
Bupropion w/o DRD2 A1 Allele7.588
Bupropion With DRD2 A1 Allele8.362
Placebo w/o DRD2 A1 Allele8.65
Placebo With DRD2 A1 Allele10.799

Abstinence at 6 Months by DRD2 A1 Allele

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 6 Month ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)

,,,,,
Interventionprobability (Least Squares Mean)
Emotional Reactivity (ORB) to Cigarette StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion w/o DRD2 A1 Allele0.0010.00100.001
Bupropion With DRD2 A1 Allele-0.001-0.002-0.001-0.001
Placebo w/o DRD2 A1 Allele0000
Placebo With DRD2 A1 Allele-0.005-0.004-0.004-0.004
Varenicline w/o DRD2 A1 Allele0.0030.0030.0030.003
Varenicline With DRD2 A1 Allele-0.001-0.0010-0.001

Emotional Reactivity By Pharmacotherapy

Emotional reactivity measured by the peak eye blink electromyography (EMG) of the orbicularis oculi (ORB) muscle responses to acoustic startle probe delivered during the presentation of emotionally valent stimuli (pleasant, unpleasant, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month

,,
Interventionmicrovolts (Least Squares Mean)
Emotional Reactivity (ORB) to Cigarette StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion64.773.165.464.9
Placebo65.665.664.772.5
Varenicline66.670.966.759.6

Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele

The emotional reactivity (ORB EMG) of smokers during cessation will be moderated by genotype. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month

,,,,,
Interventionmicrovolts (Least Squares Mean)
Emotional Reactivity (ORB) to Cigarette StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion w/o DRD2 A1 Allele66.278.671.373.9
Bupropion With DRD2 A1 Allele6671.363.361.2
Placebo w/o DRD2 A1 Allele67.37468.579.7
Placebo With DRD2 A1 Allele68.168.163.867.8
Varenicline w/o DRD2 A1 Allele66.570.565.555.3
Varenicline With DRD2 A1 Allele69.975.17267.2

Heart Rate Response

Heart Rate Response. A single value was estimated by averaging within the specific time interval. During a quit attempt, smokers were evaluated on how they react to smoking related cues. An interaction term was then formed by the reactivity to smoking stimulus and genotype. (NCT00507728)
Timeframe: Baseline to 1 month

,,,,,
Interventionbeats per minute (Least Squares Mean)
Heart Rate response to Cigarette StimuliHeart Rate response to Negative StimuliHeart Rate response to Positive StimuliHeart Rate response to Neutral Stimuli
Bupropion w/o DRD2 A1 Allele71.42771.07771.51871.706
Bupropion With DRD2 A1 Allele69.83669.59570.40470.234
Placebo w/o DRD2 A1 Allele65.96665.76865.78765.237
Placebo With DRD2 A1 Allele65.27665.56965.92766.04
Varenicline w/o DRD2 A1 Allele69.73169.56269.15169.621
Varenicline With DRD2 A1 Allele68.65268.07868.71168.969

Measures of Smoking Satisfaction and Psychological Reward Using the Modified Cigarette Evaluation Questionnaire (mCEQ) Subscales

Modified Cigarette Evaluation Questionnaire (mCEQ). mCEQ Smoking satisfaction: range (1-21); mCEQ Psychological Reward: range(1-35); mCEQ Aversion: range (1-14); mCEQ Enjoyment of Resp.Tract Sens: range (1-7); mCEQ Craving Reduction: range (1-7). For all scales of mCEQ higher scores indicate worse outcomes (greater intensity of smoking effect). Scores of mCEQ Smoking satisfaction, mCEQ psychological reward and mCEQ aversion were summed to create the subscales. mCEQ Enjoyment of Resp Tract Sens and mCEQ Craving Reduction were single items. (NCT00507728)
Timeframe: Baseline to 8 months

,,,,,
Interventionscore on a scale (Least Squares Mean)
Smoking SatisfactionPsychological RewardAversionEnjoyment of Respiratory Tract SensationCraving Reduction
Bupropion w/o DRD2 A1 Allele4.0642.5191.9884.0964.564
Bupropion With DRD2 A1 Allele3.3692.7231.791.9556.628
Placebo w/o DRD2 A1 Allele3.0253.5751.8083.7114.486
Placebo With DRD2 A1 Allele3.5153.2461.692.7834.673
Varenicline w/o DRD2 A1 Allele2.8952.8191.6121.9124.531
Varenicline With DRD2 A1 Allele2.5912.1551.6941.7033.952

Skin Conductance Response

Skin conductance response (SCR) amplitude measured by placing an electrodermal response transducer on the fore and ring fingers of the participants non-dominant hand, and heart rate (HR) was collected by placing a photoelectric pulse plethysmogram transducer on the middle finger of the participants non-dominant hand, during the presentation of emotionally valent stimuli (positive, negative, neutral, and smoking-related pictures). A single value was estimated by averaging within the specific time interval. (NCT00507728)
Timeframe: Baseline to 1 month

,,,,,
InterventionMicrosiemens (Least Squares Mean)
Skin conductance to Cigarette StimuliSkin conductance to Negative StimuliSkin conductance to Positive StimuliSkin conductance to Neutral Stimuli
Bupropion w/o DRD2 A1 Allele2.2752.312.2992.369
Bupropion With DRD2 A1 Allele1.7971.6951.71.699
Placebo w/o DRD2 A1 Allele2.2722.3552.2962.362
Placebo With DRD2 A1 Allele2.4432.4852.5652.559
Varenicline w/o DRD2 A1 Allele2.3012.2952.2562.261
Varenicline With DRD2 A1 Allele2.0161.9691.9842.017

Smoking Abstinence at 3 Months

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 months

,,
Interventionprobability (Least Squares Mean)
Emotional Reactivity (ORB) to Cigarette StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion-0.01-0.009-0.01-0.008
Placebo-0.008-0.007-0.007-0.007
Varenicline-0.003-0.004-0.003-0.004

Smoking Abstinence at 3 Months by DRD2 A1 Allele

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Baseline to 3 Month

,,,,,
Interventionprobability (Least Squares Mean)
Emotional Reactivity (ORB) to Cigarette StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion w/o DRD2 A1 Allele0000.001
Bupropion With DRD2 A1 Allele-0.003-0.004-0.003-0.002
Placebo w/o DRD2 A1 Allele-0.001-0.001-0.001-0.001
Placebo With DRD2 A1 Allele-0.004-0.004-0.004-0.003
Varenicline w/o DRD2 A1 Allele0.0010.0020.0010.001
Varenicline With DRD2 A1 Allele-0.004-0.005-0.005-0.005

Smoking Abstinence at 6 Months

Values represent change in probability of abstinence for unit change in emotional reactivity. Abstinence data collected using a timeline follow-back (TLFB) procedure. Continuous Abstinence was defined as no smoking within the last 4 weeks of treatment. It is scored as 0 if the participant smoked during the specific interval, and 1 if the participant abstained from smoking. (NCT00507728)
Timeframe: Abstinence at 6 Months ( the effects shown are the increase/decrease in probability of abstinence for 1 unit increase in the predictor)

,,
Interventionprobability (Least Squares Mean)
Emotional Reactivity (ORB) to Cigaretee StimuliEmotional Reactivity (ORB) to Negative StimuliEmotional Reactivity (ORB) to Positive StimuliEmotional Reactivity (ORB) to Neutral Stimuli
Bupropion-0.002-0.003-0.003-0.001
Placebo-0.006-0.005-0.005-0.005
Varenicline0.0070.0080.010.008

Symptoms of Nicotine Withdrawal and Negative Affect Using Positive and Negative Affect Scale (PANAS)

Symptoms of nicotine withdrawal and negative affect were measured using the Positive and Negative Affect Scale (PANAS). The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (not at all) to 5 (very much). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

,,,,,
Interventionscore on a scale (Least Squares Mean)
Positive AffectNegative Affect
Bupropion w/o DRD2 A1 Allele36.42915.782
Bupropion With DRD2 A1 Allele35.28116.385
Placebo w/o DRD2 A1 Allele33.67218.017
Placebo With DRD2 A1 Allele33.98418.902
Varenicline w/o DRD2 A1 Allele35.50715.93
Varenicline With DRD2 A1 Allele37.31514.98

Symptoms of Nicotine Withdrawal Using the Wisconsin Smoking Withdrawal Scale (WSWS)

Symptoms of nicotine withdrawal measured using Wisconsin Smoking Withdrawal Scale (WSWS). The Wisconsin Withdrawal Scale (WSWS) contains 7 factors: Anger, Anxiety, Sadness, Concentration, Craving, Sleep, and Hunger. WSWS consists of 28 items that are scored on a 5-point Likert type scale (0 = strongly disagree, 4 = strongly agree). A single value was estimated by averaging within the specific time interval. Higher values represent worse outcome. The average value was estimated from Baseline to 8 months (NCT00507728)
Timeframe: Baseline to 8 months

,,,,,
Interventionscore on a scale (Least Squares Mean)
AngerAnxietyConcentrationCravingHungerSadnessSleep
Bupropion w/o DRD2 A1 Allele4.286.5874.2386.8149.794.0059.672
Bupropion With DRD2 A1 Allele4.416.5873.9356.7811.0824.3389.528
Placebo w/o DRD2 A1 Allele5.5847.7854.7649.02411.2075.2939.078
Placebo With DRD2 A1 Allele5.7527.9154.9518.69611.0445.8658.629
Varenicline w/o DRD2 A1 Allele4.3946.2183.7436.64611.0164.2467.721
Varenicline With DRD2 A1 Allele4.2225.8733.4076.25210.7073.7388.153

Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score

Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning (NCT00519428)
Timeframe: 12 weeks

Interventionunits on the SAS scale (Mean)
Escitalopram + Bupropion2.65
Escitalopram2.63
Bupropion2.74

Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)

"The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).~The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction." (NCT00519428)
Timeframe: 12 weeks

Interventionunits on the Q-LES-Q scale (Mean)
Escitalopram + Bupropion3.0
Escitalopram3.0
Bupropion3.1

Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) <= 7, With no HAM-D 17 >7 Through Week 12

Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] > 7 once HAMD-D 17 <= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate. (NCT00519428)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Escitalopram + Bupropion52
Escitalopram46
Bupropion34

Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)

"Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.~0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression~≥ 23 = Very Severe Depression" (NCT00519428)
Timeframe: 12 weeks

Interventionunits on Hamilton Rating Scale for Depre (Mean)
Escitalopram + Bupropion10
Escitalopram9
Bupropion12

Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7

Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05. (NCT00519428)
Timeframe: 12 weeks

Interventionweeks (Mean)
Escitalopram + Bupropion8
Escitalopram9
Bupropion10

7-day Point Prevalence of Smoking Abstinence

"Number of participants who report Not Smoking (not even a puff) in past 7 days when asked at week 8" (NCT01015170)
Timeframe: End of Treatment (8 weeks after Zyban start date)

Interventionparticipants (Number)
Still smokingQuit smoking
Nicotine Replacement & Behavioural Support109106

Reviews

26 reviews available for bupropion and Depression

ArticleYear
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
    Journal of medicinal chemistry, 2014, Oct-23, Volume: 57, Issue:20

    Topics: Alkaloids; Antidepressive Agents; Azetidines; Azocines; Depression; Humans; Ligands; Molecular Targe

2014
Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.
    JAMA psychiatry, 2022, 04-01, Volume: 79, Issue:4

    Topics: Adult; Antidepressive Agents; Autoreceptors; Bupropion; Depression; Drug Therapy, Combination; Human

2022
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.
    Neuropharmacology, 2023, Feb-01, Volume: 223

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Discovery; Ketamine; United States

2023
A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult.
    Drugs & aging, 2023, Volume: 40, Issue:9

    Topics: Aged; Bupropion; Cognitive Dysfunction; Depression; Humans

2023
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.
    CNS drugs, 2023, Volume: 37, Issue:10

    Topics: Adult; Antidepressive Agents; Bupropion; Depression; Depressive Disorder, Major; Dextromethorphan; H

2023
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    The Cochrane database of systematic reviews, 2021, 01-18, Volume: 1

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Attention Deficit Disorder with Hyperactiv

2021
Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2021, Volume: 24, Issue:6

    Topics: Bupropion; Cost-Benefit Analysis; Depression; Drug Costs; Electronic Nicotine Delivery Systems; Huma

2021
Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis.
    PloS one, 2017, Volume: 12, Issue:12

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Male; Smoking; Smok

2017
Pharmacotherapy for Perinatal Depression.
    Clinical obstetrics and gynecology, 2018, Volume: 61, Issue:3

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Tricyclic; Autism Spectru

2018
Meta-analysis: Second generation antidepressants and headache.
    Journal of affective disorders, 2018, 08-15, Volume: 236

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double-

2018
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
    Journal of affective disorders, 2019, 05-01, Volume: 250

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disor

2019
[Antidepressants in epilepsy].
    Revista de neurologia, 2013, Aug-01, Volume: 57, Issue:3

    Topics: Anticonvulsants; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials

2013
Bupropion in the depression-related sexual dysfunction: a systematic review.
    CNS & neurological disorders drug targets, 2014, Volume: 13, Issue:6

    Topics: Bupropion; Databases, Bibliographic; Depression; Female; Humans; Male; Selective Serotonin Reuptake

2014
Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
    Inflammatory bowel diseases, 2016, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Affect; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Bupropion

2016
Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review.
    Acta neuropsychiatrica, 2017, Volume: 29, Issue:3

    Topics: Acetamides; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepres

2017
Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?
    The international journal of biochemistry & cell biology, 2009, Volume: 41, Issue:11

    Topics: Animals; Binding Sites; Bupropion; Catecholamine Plasma Membrane Transport Proteins; Depression; Hum

2009
Use of sustained-release bupropion in specific patient populations for smoking cessation.
    Drugs, 2002, Volume: 62 Suppl 2

    Topics: Alcoholism; Body Weight; Bupropion; Delayed-Action Preparations; Depression; Dopamine Uptake Inhibit

2002
Review of bupropion for smoking cessation.
    Drug and alcohol review, 2003, Volume: 22, Issue:2

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Delayed-Action Prepara

2003
[Treatment of tobacco dependence: brief and intensive clinical intervention].
    La Tunisie medicale, 2004, Volume: 82, Issue:1

    Topics: Anxiety; Bupropion; Cognitive Behavioral Therapy; Depression; Dopamine Uptake Inhibitors; Ganglionic

2004
Psychiatric morbidity in psoriasis: a review.
    The Australasian journal of dermatology, 2004, Volume: 45, Issue:3

    Topics: Adaptation, Psychological; Adrenal Cortex Hormones; Antidepressive Agents; Bupropion; Depression; Hu

2004
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria

2008
Review: Bupropion and SSRI-induced side effects.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7

    Topics: Affective Symptoms; Bupropion; Depression; Dopamine Uptake Inhibitors; Drug Interactions; Drug Thera

2008
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bu

1997
Nicotine dependence: the role for antidepressants and anxiolytics.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:2

    Topics: Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorde

2002
Major depression: its recognition and treatment. Part 2. Second-generation and newer antidepressants.
    American pharmacy, 1992, Volume: NS32, Issue:11

    Topics: Antidepressive Agents; Bupropion; Clomipramine; Depression; Female; Fluoxetine; Humans; Male; Maprot

1992
Bupropion: new therapy for depression.
    American family physician, 1990, Volume: 41, Issue:6

    Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones

1990

Trials

43 trials available for bupropion and Depression

ArticleYear
Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2022, Volume: 30, Issue:9

    Topics: Aging; Antidepressive Agents; Brain; Bupropion; Depression; Humans; Magnetic Resonance Imaging

2022
The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial.
    Depression and anxiety, 2022, Volume: 39, Issue:5

    Topics: Bupropion; Depression; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Polyesters; Sm

2022
Emotional blunting with bupropion and serotonin reuptake inhibitors in three randomized controlled trials for acute major depressive disorder.
    Journal of affective disorders, 2022, 12-01, Volume: 318

    Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Humans;

2022
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
    Psychological medicine, 2023, Volume: 53, Issue:13

    Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major

2023
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
    Psychological medicine, 2023, Volume: 53, Issue:13

    Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major

2023
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
    Psychological medicine, 2023, Volume: 53, Issue:13

    Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major

2023
Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression.
    Psychological medicine, 2023, Volume: 53, Issue:13

    Topics: Aged; Antidepressive Agents; Brain; Brain Mapping; Bupropion; Depression; Depressive Disorder, Major

2023
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023, 04-06, Volume: 25, Issue:5

    Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline

2023
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023, 04-06, Volume: 25, Issue:5

    Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline

2023
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023, 04-06, Volume: 25, Issue:5

    Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline

2023
Effectiveness of Bupropion and Varenicline for Smokers With Baseline Depressive Symptoms.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023, 04-06, Volume: 25, Issue:5

    Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Smokers; Varenicline

2023
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
    The New England journal of medicine, 2023, Mar-23, Volume: 388, Issue:12

    Topics: Aged; Antidepressive Agents; Aripiprazole; Bupropion; Depression; Drug Therapy, Combination; Humans;

2023
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
    The New England journal of medicine, 2023, Aug-03, Volume: 389, Issue:5

    Topics: Antidepressive Agents; Bipolar Disorder; Bupropion; Canada; Depression; Double-Blind Method; Escital

2023
A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures.
    Contemporary clinical trials, 2020, Volume: 91

    Topics: Age Factors; Antidepressive Agents, Second-Generation; Breast Neoplasms; Bupropion; Cancer Survivors

2020
Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.
    The international journal of neuropsychopharmacology, 2017, 11-01, Volume: 20, Issue:11

    Topics: Adult; Antidepressive Agents; Biomarkers; Bupropion; Depression; Drug Therapy, Combination; Female;

2017
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
    Journal of affective disorders, 2018, Volume: 234

    Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body

2018
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
    Depression and anxiety, 2019, Volume: 36, Issue:4

    Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio

2019
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
    The Journal of clinical psychiatry, 2018, 12-18, Volume: 80, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Aripiprazole; Bupropion; Cost-Benefit Analysi

2018
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
    JAMA psychiatry, 2013, Volume: 70, Issue:5

    Topics: Adolescent; Adult; Affect; Aged; Benzazepines; Bupropion; Combined Modality Therapy; Counseling; Del

2013
Increase in work productivity of depressed individuals with improvement in depressive symptom severity.
    The American journal of psychiatry, 2013, Volume: 170, Issue:6

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Cyclohexan

2013
Examining relations between alpha power as well as anterior cingulate cortex-localized theta activity and response to single or dual antidepressant pharmacotherapies.
    Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:6

    Topics: Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Citalopram;

2014
Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Depression; Double-Blind Method; Drug The

2014
A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms?
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2015, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Bupropion; Chronic Disease; Cognitive Behavioral Therapy; Counseling; Depre

2015
Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation.
    Journal of substance abuse treatment, 2015, Volume: 52

    Topics: Adult; Bupropion; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male;

2015
Treatment of maternal depression in a medication clinical trial and its effect on children.
    The American journal of psychiatry, 2015, Volume: 172, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Child; Child of Impaired Parents; Citalo

2015
Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2009, Volume: 11, Issue:10

    Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; De

2009
Do smokers know what we're talking about? The construct validity of nicotine dependence questionnaire measures.
    Psychological assessment, 2009, Volume: 21, Issue:4

    Topics: Administration, Oral; Adult; Bupropion; Chewing Gum; Combined Modality Therapy; Counseling; Depressi

2009
A bupropion smoking cessation clinical trial for cancer patients.
    Cancer causes & control : CCC, 2010, Volume: 21, Issue:6

    Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi

2010
The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:7

    Topics: Adult; Antidepressive Agents; Bupropion; Depression; Female; Humans; Male; Middle Aged; Predictive V

2010
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Journal of affective disorders, 2011, Volume: 133, Issue:3

    Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram;

2011
Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
    Journal of the National Cancer Institute, 2012, Feb-22, Volume: 104, Issue:4

    Topics: Adult; Aged; Biomarkers; Black or African American; Bupropion; Cotinine; Depression; Dopamine Uptake

2012
Bupropion pre-treatment of endotoxin-induced depressive symptoms.
    Brain, behavior, and immunity, 2013, Volume: 31

    Topics: Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Bupropion; Chemokines; Cross-Over S

2013
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Obesity research, 2002, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa

2002
Targeting smokers at increased risk for relapse: treating women and those with a history of depression.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2003, Volume: 5, Issue:1

    Topics: Administration, Cutaneous; Bupropion; Depression; Dopamine Uptake Inhibitors; Female; Humans; Male;

2003
Assessing the effects of bupropion SR on mood dimensions of depression.
    Journal of affective disorders, 2004, Volume: 78, Issue:3

    Topics: Administration, Oral; Adult; Affect; Antidepressive Agents, Second-Generation; Bupropion; Depression

2004
Depressed smokers and stage of change: implications for treatment interventions.
    Drug and alcohol dependence, 2004, Nov-11, Volume: 76, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Depression; Female; Humans;

2004
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2005, Volume: 7, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression;

2005
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Psycho-oncology, 2006, Volume: 15, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati

2006
Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
    Archives of internal medicine, 2005, Oct-24, Volume: 165, Issue:19

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Depression; D

2005
The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2005, Volume: 7, Issue:6

    Topics: Adult; Attitude to Health; Black or African American; Bupropion; Comorbidity; Depression; Dopamine U

2005
Bupropion improves sexual functioning in depressed minority women: an open-label switch study.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors;

2006
Bupropion and cognitive-behavioral treatment for depression in smoking cessation.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2007, Volume: 9, Issue:7

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Combined M

2007
Comparative efficacy and safety of bupropion and placebo in the treatment of depression.
    Psychopharmacology, 1983, Volume: 79, Issue:4

    Topics: Adult; Bupropion; Clinical Trials as Topic; Depression; Double-Blind Method; Female; Humans; Male; M

1983
Bupropion: study of treatment in depressed patients.
    The Journal of the Florida Medical Association, 1983, Volume: 70, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depression; Fem

1983
Determination of plasma bupropion and its relationship to therapeutic effect.
    Biomedical mass spectrometry, 1984, Volume: 11, Issue:12

    Topics: Amitriptyline; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depression; Double-Blind

1984
Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.
    Journal of clinical pharmacology, 1995, Volume: 35, Issue:9

    Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamin

1995
A comparison of sustained-release bupropion and placebo for smoking cessation.
    The New England journal of medicine, 1997, Oct-23, Volume: 337, Issue:17

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression;

1997
A comparison of sustained-release bupropion and placebo for smoking cessation.
    The New England journal of medicine, 1997, Oct-23, Volume: 337, Issue:17

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression;

1997
A comparison of sustained-release bupropion and placebo for smoking cessation.
    The New England journal of medicine, 1997, Oct-23, Volume: 337, Issue:17

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression;

1997
A comparison of sustained-release bupropion and placebo for smoking cessation.
    The New England journal of medicine, 1997, Oct-23, Volume: 337, Issue:17

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression;

1997
Safety profile of sustained-release bupropion in depression: results of three clinical trials.
    Clinical therapeutics, 1999, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Del

1999
Efficacy of sustained-release bupropion in neuropathic pain: an open-label study.
    The Clinical journal of pain, 2000, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action

2000

Other Studies

83 other studies available for bupropion and Depression

ArticleYear
Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?
    Psychiatria Danubina, 2022,Summer, Volume: 34, Issue:2

    Topics: Bupropion; Depression; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions;

2022
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
    Progress in neuro-psychopharmacology & biological psychiatry, 2022, 12-20, Volume: 119

    Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methy

2022
Dextromethorphan/bupropion (Auvelity) for depression.
    The Medical letter on drugs and therapeutics, 2022, 12-26, Volume: 64, Issue:1666

    Topics: Bupropion; Depression; Dextromethorphan; Humans; Selective Serotonin Reuptake Inhibitors; Smoking Ce

2022
Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
    American family physician, 2023, Volume: 108, Issue:3

    Topics: Aged; Aripiprazole; Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Humans; Nortrip

2023
Increased depression-like behaviors with altered brain dopamine metabolisms in male mice housed in large cages are alleviated by bupropion.
    European journal of pharmacology, 2023, Dec-05, Volume: 960

    Topics: Anhedonia; Animals; Brain; Bupropion; Depression; Dopamine; Female; Housing; Male; Mice; Norepinephr

2023
Using prefrontal and midline right frontal EEG-derived theta cordance and depressive symptoms to predict the differential response or remission to antidepressant treatment in major depressive disorder.
    Psychiatry research. Neuroimaging, 2020, 08-30, Volume: 302

    Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Electro

2020
Delayed Onset of Bupropion-Induced Urticaria.
    The primary care companion for CNS disorders, 2020, 07-30, Volume: 22, Issue:4

    Topics: Adolescent; Bupropion; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Humans; Male; Urticaria

2020
Formulation, Characterization and Comparative Pharmacokinetic Study of Bupropion Floating Raft System as a Promising Approach for Treating Depression.
    Journal of pharmaceutical sciences, 2020, Volume: 109, Issue:11

    Topics: Bupropion; Delayed-Action Preparations; Depression; Drug Delivery Systems; Humans; Solubility; Table

2020
Methylglyoxal-Mediated Dopamine Depletion, Working Memory Deficit, and Depression-Like Behavior Are Prevented by a Dopamine/Noradrenaline Reuptake Inhibitor.
    Molecular neurobiology, 2021, Volume: 58, Issue:2

    Topics: Animals; Bupropion; Depression; Dopamine; Dopamine Uptake Inhibitors; Female; Glutathione; Immobiliz

2021
Evidence of hypoglycemic anhedonia and modulation by bupropion in rats.
    Pharmacology, biochemistry, and behavior, 2021, Volume: 203

    Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Appetitive Behavior; Bupropion; Deoxyg

2021
A 19-Year-Old Woman with a History of Depression and Fatal Cardiorespiratory Failure Following an Overdose of Prescribed Bupropion.
    The American journal of case reports, 2021, Jul-26, Volume: 22

    Topics: Adolescent; Adult; Bupropion; Depression; Drug Overdose; Female; Humans; Seizures; Shock, Cardiogeni

2021
Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in depression.
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2018, 03-19, Volume: 373, Issue:1742

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Emotions; Female; Humans; Ma

2018
Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.
    Psychopharmacology, 2018, Volume: 235, Issue:9

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Fluoxetine; Ganglia, Spinal; Humans

2018
Homicidal Ideation and Individuals on the Autism Spectrum.
    Journal of forensic sciences, 2019, Volume: 64, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder; Bup

2019
Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice.
    Chronobiology international, 2019, Volume: 36, Issue:9

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Circadian Rhythm; Depression; Dopamine;

2019
The effect of bupropion augmentation of minocycline in the treatment of depression.
    Acta neurobiologiae experimentalis, 2019, Volume: 79, Issue:2

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Bupropion; Depression; Depressive Disorder;

2019
Varenicline may reduce negative effect while aiding smoking cessation.
    Evidence-based medicine, 2014, Volume: 19, Issue:1

    Topics: Benzazepines; Bupropion; Counseling; Depression; Female; Humans; Male; Nicotinic Agonists; Quinoxali

2014
Varenicline, smoking cessation, and neuropsychiatric adverse events.
    The American journal of psychiatry, 2013, Volume: 170, Issue:12

    Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Mal

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive

2013
Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study.
    BMJ (Clinical research ed.), 2013, Oct-11, Volume: 347

    Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Cohort Studies; Depression; England; Female; Human

2013
Still not clear that smoking cessation drugs do not cause psychiatric symptoms.
    BMJ (Clinical research ed.), 2013, Nov-27, Volume: 347

    Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Sm

2013
Authors' reply to Davies.
    BMJ (Clinical research ed.), 2013, Nov-27, Volume: 347

    Topics: Benzazepines; Bupropion; Depression; Female; Humans; Male; Quinoxalines; Self-Injurious Behavior; Sm

2013
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Dec-04, Volume: 33, Issue:49

    Topics: Adenosine A2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Sec

2013
Effects of bupropion and pramipexole on cell proliferation in the hippocampus of adrenocorticotropic hormone-treated rats.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:2

    Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Benzothiazoles; Bupropion; Cell Prolife

2014
Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion.
    Journal of affective disorders, 2014, Volume: 162

    Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depression; Drug Therapy, Combination; Female

2014
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Animals; Antidepressive Agents; Benzazepines; Benzophenones; Bupropion; Cannabinoid Receptor Antagon

2014
Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington's Disease with Dopaminergic Dysfunction.
    Journal of Huntington's disease, 2012, Volume: 1, Issue:2

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Dopamine Uptake Inhibitors;

2012
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2014, Volume: 65, Issue:5

    Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; I

2014
Effect of Treating Mothers' Depression on Children's Well-Being.
    The American journal of psychiatry, 2015, Volume: 172, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Child of Impaired Parents; Citalopram; Depressi

2015
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.
    The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10

    Topics: Adult; Bupropion; Cardiovascular Diseases; Depression; Dopamine Uptake Inhibitors; Female; Humans; M

2015
Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice.
    Pharmacology, biochemistry, and behavior, 2015, Volume: 139, Issue:Pt A

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression; Drug Synergism; Drug Therap

2015
Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.
    Behavioural pharmacology, 2016, Volume: 27, Issue:4

    Topics: Analgesics; Analgesics, Opioid; Animals; Bupropion; Depression; Disease Models, Animal; Dose-Respons

2016
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.
    American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:4

    Topics: Adult; Amniotic Fluid; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Feta

2016
Do COPD treatment guidelines correctly address the treatment of smoking?
    Archivos de bronconeumologia, 2016, Volume: 52, Issue:12

    Topics: Bupropion; Depression; Humans; Nicotinic Agonists; Practice Guidelines as Topic; Pulmonary Disease,

2016
Wellbutrin versus generic bupropion.
    The Medical letter on drugs and therapeutics, 2008, Jul-14, Volume: 50, Issue:1290

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; Dopami

2008
Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?
    Behavioural brain research, 2008, Dec-01, Volume: 194, Issue:1

    Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents, Second-Generatio

2008
Severe constipation associated with extended-release bupropion therapy.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Aug-15, Volume: 65, Issue:16

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cathartics; Constipation; Delayed-Action

2008
Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion.
    Psychiatry and clinical neurosciences, 2008, Volume: 62, Issue:4

    Topics: Animals; Bupropion; Depression; Dose-Response Relationship, Drug; Drug Administration Routes; Gene E

2008
Nicotine exposure during adolescence induces a depression-like state in adulthood.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:6

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De

2009
Struck from behind: maintaining quality of life with chronic low back pain.
    The journal of pain, 2009, Volume: 10, Issue:9

    Topics: Accidents, Traffic; Activities of Daily Living; Adult; Analgesics, Opioid; Bupropion; Depression; Do

2009
Bupropion for depression in schizophrenia: a case report.
    Pharmacopsychiatry, 2010, Volume: 43, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Humans; Male; Schizophrenia

2010
Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant?
    The Journal of family practice, 2010, Volume: 59, Issue:3

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Co

2010
Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:2

    Topics: Animals; Bupropion; Chromatography, High Pressure Liquid; Cosyntropin; Depression; Dopamine; Dopamin

2010
Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.
    Psychopharmacology, 2010, Volume: 212, Issue:4

    Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depression;

2010
Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
    Medical hypotheses, 2010, Volume: 75, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; Humans;

2010
Regulatory role of the dopamine and norepinephrine transporters in pentylenetetrazol-kindled mice: association with effect of antidepressants.
    European journal of pharmacology, 2011, Dec-30, Volume: 673, Issue:1-3

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Bupropion;

2011
Suicidal behavior and depression in smoking cessation treatments.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Adult; Benzazepines; Bupropion; Depression; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic A

2011
Delayed, fatal cardiotoxicity associated with bupropion and citalopram overdose.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxins; Citalopram; Delayed-Action

2012
Reward responsiveness and fatigue in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:2

    Topics: Adult; Anxiety; Attention; Bupropion; Citalopram; Cognition; Depression; Disability Evaluation; Diso

2013
[Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy].
    Archivos de bronconeumologia, 2002, Volume: 38, Issue:8

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Depression; F

2002
Smoking and depression.
    The Harvard mental health letter, 2002, Volume: 19, Issue:2

    Topics: Bupropion; Depression; Genetic Predisposition to Disease; Humans; Smoking; Tobacco Use Disorder; Uni

2002
Antidepressant-like effects in various mice strains in the tail suspension test.
    Behavioural brain research, 2003, Aug-14, Volume: 143, Issue:2

    Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An

2003
Bupropion should be included in article on antidepressants.
    American family physician, 2004, Jun-01, Volume: 69, Issue:11

    Topics: Antidepressive Agents; Bupropion; Depression; Humans; Selective Serotonin Reuptake Inhibitors

2004
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
    Consumer reports, 2004, Volume: 69, Issue:10

    Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression;

2004
Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test.
    European journal of pharmacology, 2004, Nov-19, Volume: 504, Issue:3

    Topics: Animals; Benzazepines; Bupropion; Depression; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose

2004
Acceptance of nicotine dependence treatment among currently depressed smokers.
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2005, Volume: 7, Issue:2

    Topics: Adult; Behavior Therapy; Bupropion; Community Mental Health Centers; Counseling; Depression; Dopamin

2005
Bupropion-induced subacute cutaneous lupus erythematosus.
    The Australasian journal of dermatology, 2005, Volume: 46, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Immunosuppre

2005
Assessment and management of women's sexual dysfunctions: problematic desire and arousal.
    The journal of sexual medicine, 2005, Volume: 2, Issue:3

    Topics: Adult; Androgens; Bupropion; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopa

2005
Psychopharmacology of smoking cessation in patients with mental illness.
    Journal of psychiatry & neuroscience : JPN, 2006, Volume: 31, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Anxiety; Arousal; Bupropion; Citalopram; Depression; Depre

2006
Editorial.
    Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:4

    Topics: Body Mass Index; Bupropion; Depression; Dopamine Uptake Inhibitors; Health Behavior; Humans; Life St

2006
Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Delirium; Depressi

2006
Bupropion therapy for pathological gambling.
    The Annals of pharmacotherapy, 2007, Volume: 41, Issue:3

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depression; Gambli

2007
Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    European journal of pharmacology, 2007, Jul-30, Volume: 568, Issue:1-3

    Topics: Animals; Antidepressive Agents, Second-Generation; Arginine; Behavior, Animal; Body Temperature; Bra

2007
Bupropion-induced parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Sep-15, Volume: 22, Issue:12

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Humans; Male; Middle Aged; Parkinso

2007
Treatment of comorbid attention deficit hyperactivity disorder and depression in pediatric patient.
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2007, Volume: 29, Issue:2

    Topics: Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bupropion;

2007
[Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
    MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2

    Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Bupropion; Controlled Clinical Trials a

2007
Prolonged QT associated with an overdose of trazodone.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Drug Overdose; Electrocardio

2007
New directions in the treatment of depression: bupropion.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2

    Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones

1983
Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection.
    Journal of pharmaceutical sciences, 1984, Volume: 73, Issue:8

    Topics: Bupropion; Chromatography, High Pressure Liquid; Depression; Humans; Propiophenones; Spectrophotomet

1984
A clinical trial of bupropion in the treatment of depressed outpatients.
    Minnesota medicine, 1984, Volume: 67, Issue:9

    Topics: Adult; Aged; Ambulatory Care; Bupropion; Cognition Disorders; Depression; Drug Evaluation; Drug Inte

1984
Two multicenter studies of the antidepressant effects of bupropion HCl versus placebo.
    Psychopharmacology bulletin, 1980, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Depression; Double-Blind Method; Drug Eva

1980
Absence of orthostatic hypotension in depressed patients treated with bupropion.
    Progress in neuro-psychopharmacology, 1981, Volume: 5, Issue:5-6

    Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Blood Pressure; Bupropion; Depression; Ele

1981
Excretion of bupropion in breast milk.
    The Annals of pharmacotherapy, 1993, Volume: 27, Issue:4

    Topics: Adult; Breast Feeding; Bupropion; Depression; Female; Humans; Infant; Male; Milk, Human

1993
Eosinophilia associated with bupropion.
    The Annals of pharmacotherapy, 1995, Volume: 29, Issue:9

    Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Eosinophilia; Female; Humans;

1995
Serum sickness induced by bupropion.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:9

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Middle Aged; Psycho

1999
Amphetamine positive toxicology screen secondary to bupropion.
    Depression and anxiety, 2000, Volume: 12, Issue:1

    Topics: Aged; Amphetamine; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Chromatogr

2000
[Successful treatment of depression in a Parkinson disease patient with bupropion].
    Nederlands tijdschrift voor geneeskunde, 2000, Nov-04, Volume: 144, Issue:45

    Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; F

2000
Bupropion-induced acute dystonia.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:2

    Topics: Acute Disease; Adult; Bupropion; Buspirone; Depression; Dopamine Uptake Inhibitors; Dose-Response Re

2002
Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department.
    The Journal of emergency medicine, 2002, Volume: 22, Issue:3

    Topics: Adult; Alcohol Withdrawal Seizures; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; A

2002
Bupropion.
    American family physician, 1991, Volume: 43, Issue:6

    Topics: Antidepressive Agents; Bupropion; Depression; Drug Administration Schedule; Humans; Propiophenones

1991
Antidepressant profile of bupropion and three metabolites in mice.
    Pharmacopsychiatry, 1990, Volume: 23, Issue:4

    Topics: Animals; Antidepressive Agents; Apomorphine; Body Temperature; Bupropion; Depression; Male; Mice; Mo

1990
Bupropion reintroduced for treatment of depression.
    Clinical pharmacy, 1989, Volume: 8, Issue:9

    Topics: Antidepressive Agents; Bupropion; Depression; Humans; Propiophenones

1989